Efficient production of AAV (adeno-associated virus) vectors is a critical challenge in cell and gene therapy (CGT). Traditional transfection reagents often struggle with high costs, batch variability, and scaling difficulties. Yeasen Biotech’s Ultra PEI-AAV Transfection Reagent addresses these pain points with its innovative formulation, delivering reduced reagent usage, higher yield, and superior batch consistency.
Yeasen Biotech’s independently developed Ultra PEI-AAV Transfection Reagent is specifically designed for the large-scale production of recombinant AAV in suspension 293 cell lines. The reagent reduces transfection reagent usage by 50% while maintaining viral yield. Moreover, both viral yield and full/empty capsid ratios are significantly superior to those of the leading competitor, Brand P. This reagent not only enhances production efficiency but also reduces costs, which is crucial for the future development of CGT drugs. Cost reduction and efficiency improvement have become key trends in CGT drug development, and Yeasen Biotech’s product perfectly aligns with this market demand.
Core Highlights of Ultra PEI-AAV Transfection Reagent:
1. 50% Less Reagent Usage, Lower Costs
Ultra PEI-AAV Transfection Reagent is specifically optimized for scaled-up AAV production in suspension 293 cell lines. Its breakthrough formulation enables:
- 50% less reagent usage while maintaining unchanged viral yield.
- Improved full/empty capsid ratio, simplifying downstream purification and reducing impurities.
- Significant cost savings for large-scale production, making it an economical choice for CGT developers.
In practical applications, such as AAV production in 293F suspension cells, Ultra PEI-AAV consistently delivers high viral yield even at halved reagent usage.
2. High Transfection Efficiency, Broad Applicability
Ultra PEI-AAV Transfection Reagent excels in both reduced usage and superior transfection efficiency:
- Higher viral yield: Outperforms traditional PEI and competitors in producing AAV2, AAV5, AAV8, and AAV9 serotypes.
- Low complex volume: Optimized complex volume can be reduced to as low as 1%, addressing volume constraints in traditional processes.
This makes it an ideal solution for scalable AAV vector production, meeting the demands of both research and industrial applications.
3. GMP Production and DMF Filing
Ultra PEI-AAV Transfection Reagent is manufactured under strict GMP standards, ensuring:
- Consistent batch-to-batch quality, critical for large-scale production.
- DMF Filing: Building on the success of Hieff Trans® PEI Transfection Reagent-GMP, which has already completed DMF filing and supported multiple clients in China and the U.S., Ultra PEI-AAV GMP Edition is currently in the DMF filing process.
This ensures regulatory compliance and provides robust support for global CGT project applications.
Case Study: AAV9 Virus Packaging
 |
|
Ultra PEI-AAV Transfection Reagent vs. Competitor
- Test Conditions: DNA to transfection reagent ratios of 1:0.5 and 1:1.
- Results:
Viral Yield: Significantly higher than Competitor P.
Full/Empty Capsid Ratio: Superior to Competitor P.
- Key Insight: With 50% less reagent usage, Ultra PEI-AAV delivered higher viral yield compared to Competitor P.
Case Study: AAV5 Virus Packaging
 |
|
Ultra PEI-AAV Transfection Reagent vs. Competitor P
- Test Conditions: DNA to transfection reagent ratios of 1:0.5 and 1:0.75.
- Results:
Viral Yield: Significantly higher than Competitor P.
Full/Empty Capsid Ratio: Superior to Competitor P.
- Key Insight: At half the reagent usage, Ultra PEI-AAV achieved higher viral yield than Competitor P.
Case Study: 3-Batch GMP Product Stability Testing(AAV9-VG)
 |
|
Ultra PEI-AAV GMP Transfection Reagent vs. Competitor P
- Test Conditions: AAV9 virus packaging using 3 batches of GMP-grade reagents.
- Results:
Batch Consistency: High stability across all 3 batches.
Viral Yield: Significantly higher than Competitor P.
Full/Empty Capsid Ratio: Superior to Competitor P.
Summary
Ultra PEI-AAV Transfection Reagent revolutionizes AAV production with its low usage, reduced costs, high transfection efficiency, and scalability. By meeting the industry’s demand for efficient and cost-effective production, it provides robust support for advancements in cell and gene therapy.
Product Information
|
Product Name |
Specification |
Cat No. |
|
1 mL /10 mL /100mL |
40823ES03/40823ES10/40823ES60 |
|
|
10 mL /100 mL/1 L |
40824ES10/40824ES60/40824ES80 |
Related Product
|
Product Name |
Specification |
Cat No. |
|
100 μL/1 mL |
40802ES01/03 |
|
|
Hieff TransTM Calcium Phosphate Cell Transfection Kit |
200 T |
40803ES70 |
|
500 μL/5×500 μL |
40804ES76/86 |
|
|
100 μL/1 mL |
40806ES01/03 |
|
|
0.5 mL /1 mL |
40808ES02/03 |
|
|
100 μL/1 mL |
40809ES01/03 |
|
|
1.5 mL /10 mL /100 mL |
40820ES04/10/60 |
|
|
10 mL /100 mL/1 L |
40821ES10/60 /80 |